Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
Martin Wermke(National Center for Tumor Diseases), Cedrik M. Britten(Johannes Gutenberg University Mainz), Dejka M. Araujo(The University of Texas MD Anderson Cancer Center), M. Alper Kursunel(Immatics Biotechnologies (Germany)), Tobias A.W. Holderried(Brigham and Women's Hospital), Sapna P. Patel(JSS Dental College and Hospital), Regina Mendrzyk(Immatics Biotechnologies (Germany)), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Winfried Alsdorf(Universität Hamburg), Jason J. Luke(University of Chicago), Ali Wagdy Mohamed(Cairo University), Norbert Hilf(Immatics Biotechnologies (Germany)), Manik Chatterjee(University of Würzburg), Ran Reshef(Abramson Cancer Center), Toni Weinschenk(Immatics Biotechnologies (Germany)), Leonel F. Hernandez‐Aya(Washington University in St. Louis), Antonia Busse(Franklin University), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Andrea Mayer-Mokler(Immatics Biotechnologies (Germany)), Steffen Walter(Universität Ulm)
Cited by 3
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
|Journal of Clinical Oncology|2018|925
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803